Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia, as well as small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells. In addition, the company is involved in the discovery of a Hepatitis B drug. It has a collaboration agreement with Emmaus Life Sciences, Inc. for the preclinical development of IRAK4 inhibitor as potential anti-cancer drug. The company was founded in 2007 and is headquartered in Seongnam-si, South Korea.
Metrics to compare | 284620 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship284620PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.8x | −0.5x | |
PEG Ratio | 0.00 | −0.09 | 0.00 | |
Price/Book | 0.0x | 2.3x | 2.6x | |
Price / LTM Sales | 0.0x | 19.6x | 3.2x | |
Upside (Analyst Target) | 0.0% | 25.1% | 42.0% | |
Fair Value Upside | Unlock | −2.0% | 6.6% | Unlock |